Abstract
BackgroundRituximab (RTX) is a chimeric monoclonal antibody approved for the treatment of active rheumatoid arthritis (RA) in patients who failed to respond to tumour necrosis factor inhibitors (TNFi). Due to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have